Tags

Type your tag names separated by a space and hit enter

The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea.
Ann Pharmacother. 2010 May; 44(5):826-31.AP

Abstract

BACKGROUND

Limited evidence suggests there may be a link between fluoroquinolone use and Clostridium difficile-associated diarrhea (CDAD), but such an association remains unclear due to conflicting data.

OBJECTIVE

To determine the relationship between inpatient fluoroquinolone use and CDAD; secondary objectives included the relationship between CDAD and fluoroquinolone selection, duration of therapy, and route of administration, as well as the association between fluoroquinolones and CDAD complications.

METHODS

We conducted a retrospective, case-control study of adult inpatients diagnosed with CDAD during the period of July 2007-July 2008. In total, 174 case patients were matched on a 1:1 basis with controls. A thorough assessment of all inpatient antibiotic use was conducted, including regimens administered at our institution within the previous 8 weeks. Odds ratios were calculated using univariate logistic-regression analysis.

RESULTS

Use of fluoroquinolones was not significantly different between patients with CDAD and matching controls (OR 1.36; 95% CI 0.09 to 2.10; p = 0.16). No relationship was found between CDAD and the individual fluoroquinolones: ciprofloxacin (OR 1.36; 95% CI 0.87 to 2.12; p = 0.18), levofloxacin (OR 1.17; 95% CI 0.62 to 2.22; p = 0.63), and moxifloxacin (OR 1.34; 95% CI 0.81 to 2.20; p = 0.25). Fluoroquinolone route of administration did not differ significantly between groups for patients receiving intravenous (OR 1.20; 95% CI 0.74 to 1.94; p = 0.46) or oral (OR 0.79; 95% CI 0.44 to 1.44; p = 0.45) therapy. Complications from CDAD were not significantly increased by fluoroquinolone use (OR 1.37; 95% CI 0.72 to 2.61; p = 0.35).

CONCLUSIONS

Inpatient administration of fluoroquinolones was not associated with CDAD at our institution. Fluoroquinolone use in patients who developed CDAD was not related to higher incidences of CDAD-related complications.

Authors+Show Affiliations

Department of Pharmacy, Charleston Area Medical Center, Charleston, SC, USA. novellm@gmail.comNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20354161

Citation

Novell, Marilyn J., and Carol A. Morreale. "The Relationship Between Inpatient Fluoroquinolone Use and Clostridium Difficile-associated Diarrhea." The Annals of Pharmacotherapy, vol. 44, no. 5, 2010, pp. 826-31.
Novell MJ, Morreale CA. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Ann Pharmacother. 2010;44(5):826-31.
Novell, M. J., & Morreale, C. A. (2010). The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. The Annals of Pharmacotherapy, 44(5), 826-31. https://doi.org/10.1345/aph.1M696
Novell MJ, Morreale CA. The Relationship Between Inpatient Fluoroquinolone Use and Clostridium Difficile-associated Diarrhea. Ann Pharmacother. 2010;44(5):826-31. PubMed PMID: 20354161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. AU - Novell,Marilyn J, AU - Morreale,Carol A, Y1 - 2010/03/30/ PY - 2010/4/1/entrez PY - 2010/4/1/pubmed PY - 2010/7/17/medline SP - 826 EP - 31 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 44 IS - 5 N2 - BACKGROUND: Limited evidence suggests there may be a link between fluoroquinolone use and Clostridium difficile-associated diarrhea (CDAD), but such an association remains unclear due to conflicting data. OBJECTIVE: To determine the relationship between inpatient fluoroquinolone use and CDAD; secondary objectives included the relationship between CDAD and fluoroquinolone selection, duration of therapy, and route of administration, as well as the association between fluoroquinolones and CDAD complications. METHODS: We conducted a retrospective, case-control study of adult inpatients diagnosed with CDAD during the period of July 2007-July 2008. In total, 174 case patients were matched on a 1:1 basis with controls. A thorough assessment of all inpatient antibiotic use was conducted, including regimens administered at our institution within the previous 8 weeks. Odds ratios were calculated using univariate logistic-regression analysis. RESULTS: Use of fluoroquinolones was not significantly different between patients with CDAD and matching controls (OR 1.36; 95% CI 0.09 to 2.10; p = 0.16). No relationship was found between CDAD and the individual fluoroquinolones: ciprofloxacin (OR 1.36; 95% CI 0.87 to 2.12; p = 0.18), levofloxacin (OR 1.17; 95% CI 0.62 to 2.22; p = 0.63), and moxifloxacin (OR 1.34; 95% CI 0.81 to 2.20; p = 0.25). Fluoroquinolone route of administration did not differ significantly between groups for patients receiving intravenous (OR 1.20; 95% CI 0.74 to 1.94; p = 0.46) or oral (OR 0.79; 95% CI 0.44 to 1.44; p = 0.45) therapy. Complications from CDAD were not significantly increased by fluoroquinolone use (OR 1.37; 95% CI 0.72 to 2.61; p = 0.35). CONCLUSIONS: Inpatient administration of fluoroquinolones was not associated with CDAD at our institution. Fluoroquinolone use in patients who developed CDAD was not related to higher incidences of CDAD-related complications. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/20354161/The_relationship_between_inpatient_fluoroquinolone_use_and_Clostridium_difficile_associated_diarrhea_ L2 - https://journals.sagepub.com/doi/10.1345/aph.1M696?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -